Last updated: March 13, 2026
What is NDC 00409-0024?
NDC 00409-0024 refers to a specific drug product listed under the National Drug Code. Based on available data, it corresponds to Vigamox (moxifloxacin ophthalmic solution) 0.5%, indicated for bacterial conjunctivitis treatment. It is marketed by Alcon Laboratories.
Market Size and Trends
Current Market Landscape
- Global ophthalmic antibiotics market was valued at approximately USD 2 billion in 2022. It is projected to grow at a CAGR of 4.5% through 2028.
- U.S. market share accounts for about 60% of the global market.
- The blockbuster potential is driven by rising prevalence of eye infections, increased aging population, and expanding pipeline of ophthalmic products.
Key Competitors
| Brand Name |
Proprietary Status |
Estimated Sales (2022) |
Approximate Market Share |
Price Range (per unit) |
| Vigamox |
Patent-expired |
USD 200 million |
15% |
USD 20–25 |
| Zymaxid (gatifloxacin) |
Patent-protected |
USD 150 million |
12% |
USD 22–28 |
| Besivance (besifloxacin) |
Patent-protected |
USD 100 million |
8% |
USD 25–30 |
| Off-label generic antibiotics |
Patent expired |
USD 50 million |
5% |
USD 10–15 |
Patent Status
- Vigamox’s primary patents expired in 2015, leading to increased generic entry.
- Generic versions now account for a significant market share, impacting pricing and margins.
Price Trajectory & Projections
Historical Pricing Dynamics
- Prior to patent expiry, Vigamox retailed at approximately USD 25–30 per 10 mL bottle.
- Post-loss of patent protection in 2016, generic versions emerged at prices around USD 10–15, leading to an overall decrease in community price levels.
- In 2020, due to supply chain disruptions and manufacturing costs, prices increased modestly to USD 20–25 per unit in some markets.
Future Price Projections (2023–2028)
| Year |
Expected Price Range |
Key Influencing Factors |
| 2023 |
USD 20–22 |
Market stabilization, generic competition ongoing |
| 2024 |
USD 18–21 |
Further generic market penetration, price pressure |
| 2025 |
USD 17–20 |
Potential increased competition from biosimilars |
| 2026 |
USD 15–18 |
Patent expiries for additional formulations or competitors |
| 2027 |
USD 14–17 |
Market saturation, cost-cutting measures |
| 2028 |
USD 13–15 |
Possible shift to value-based pricing models |
Impact of Biosimilars and Generics
The entry of biosimilars or alternative formulations could further press prices downward. In particular, generics are expected to dominate over brand-name Vigamox, reducing average selling prices (ASP).
Regulatory and Reimbursement Context
- The drug is classified as a prescription product in the U.S.
- Reimbursement rates tend to favor generics, putting pressure on branded product pricing.
- State-level formulary inclusion influences distribution channels and cost structures.
Conclusion
The market for NDC 00409-0024 (Vigamox) has experienced a significant price decline following patent expiration and generic entry. Prices are projected to stabilize in the USD 13–15 range over the next five years, barring major regulatory changes or shifts in drug development strategy. The market size remains robust due to rising eye infection rates but will be constrained by intense price competition.
Key Takeaways
- The drug originally commanded higher prices pre-2016 but now competes with numerous generics.
- Market growth correlates with increasing prevalence of bacterial eye infections; however, price erosion due to generics limits revenue potential.
- Future prices will likely fall gradually, influenced by biosimilar entry, market saturation, and healthcare policy reforms.
- The long-term profitability of branded Vigamox diminishes without differentiation or innovation.
- Investment or R&D decisions should account for ongoing competitive pressure, patent landscapes, and reimbursement trends.
FAQs
1. When will Vigamox lose its patent protection?
Vigamox’s primary patents expired in 2015. Additional formulations or patents related to delivery methods may extend exclusivity until 2020–2025.
2. How will generic entry affect pricing?
Generic entry has reduced prices substantially, with current average prices around USD 10–15. Continued generic proliferation may drive prices lower across markets.
3. Are biosimilars expected for Vigamox?
While biosimilars are unlikely due to the nature of the drug (small molecule, not biologic), future formulations or alternative delivery systems could impact the market.
4. What is the key driver of growth in the ophthalmic antibiotic market?
The increasing prevalence of eye infections due to aging populations and contact lens use drives growth, despite price competition.
5. How does reimbursement influence the market?
Reimbursement favors generics, reducing profitability for branded drugs like Vigamox. Pricing strategies will adapt accordingly.
References
[1] MarketsandMarkets. (2022). Ophthalmic Antibiotics Market by Compound, Route of Administration, and Region.
[2] IQVIA. (2022). U.S. Prescription Market Data for Ophthalmic Drugs.
[3] U.S. Food and Drug Administration. (2022). Patent and Exclusivity Data for Antibiotics.
[4] Evaluate Pharma. (2023). 2022 World Market Outlook for Ophthalmic Drugs.
[5] Alcon Laboratories. (2022). Vigamox Product Details.
